National Pharmaceutical Pricing Authority (NPPA) decides to issue show cause notice to Mankind Pharma and Intas Pharmaceuticals for selling the anti-diabetic drug (Remogliflozin with Metformin) without seeking the price approval from the (NPPA) Authority.
NPPA is the autonomous body that regulates the prices of drugs that are included in the National List of Essential Medicines (NLEM). Some medicines that are not included in the list are also monitored by NPPA for preventing the companies from overcharging the consumers.
The matter came into light on December 23, while discussing 22 new drug formulations and their selling prices. The new drug being questioned is a combination of two antidiabetic medicines- Remogliflozin etabonate with Metformin hydrochloride. While fixing retail prices and processing requests from pharmaceutical companies, it was observed that the drug already existed in the market.
Since the said formulation falls under the category of regulated drugs, it was mandatory for Ahmedabad-based Mankind Pharma and Delhi-based Intas Pharmaceuticals to seek the approval of the selling price of the anti-diabetic drug, which the company failed to secure.
Arjun Juneja, Chief Operating Officer of Mankind Pharma denied offering any comments on the NPPA’s move.
Follow Us:- Twitter
For More Updates:http://pharmanewsdesk.com/